2001

Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).

2005

Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.

2006

Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

2007

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

2011

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

2013

haematologica the hematology journal Induction Therapy in Multiple Myeloma

European Myeloma Network guidelines for the management of multiple myeloma-related complications.

2014

Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26. Review.PMID: 25439696

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6. PMID:25242045

Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb; 99(2):232-42. doi: 10.3324/haematol.2013.099358.PMID:24497560

2015

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.

Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

· Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015 Oct;95(4):316-24. doi: 10.1111/ejh.12491. Epub 2015 Jan 22.PMID:25402977

Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, Dimopoulos MA, Beksac M, Alsina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. ExpertRevAnticancerTher.2015;15(7):737-48. doi: 10.1586/14737140.2015.1047770. Epub 2015 Jun 7. Erratum in: Expert Rev Anticancer Ther. 2015;15(9):1121 . PMID:26051506

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.PMID:26035255

Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.PMID:25621805

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Paul G. Richardson , Vânia T. M. Hungria , Sung-Soo Yoon , Meral Beksac , Meletios Athanasios Dimopoulos

, Ashraf Elghandour , Wieslaw W. Jedrzejczak , Andreas Guenther , Thanyaphong Na Nakorn , Noppadol Siritanaratkul , Robert L. Schlossman , Jian Hou , Philippe Moreau , Sagar Lonial , Jae Hoon Lee , Hermann Einsele , Monika Sopala , Bourras-Rezki Bengoudifa , Claudia Corrado , Florence Binlich , and Jesús F. San-Miguel 18 Received 2015 Sep 8 127:713-721; Accepted 2015 Nov 20

2016

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Antonio Palumbo, M.D., Asher Chanan‑Khan, M.D., Katja Weisel, M.D., Ajay K. Nooka, M.D., Tamas Masszi, M.D., Meral Beksac, M.D., Ivan Spicka, M.D., Vania Hungria, M.D., Markus Munder, M.D., Maria V. Mateos, M.D., Tomer M. Mark, M.D., Ming Qi, M.D., Jordan Schecter, M.D., Himal Amin, B.S., Xiang Qin, M.S., William Deraedt, Ph.D., Tahamtan Ahmadi, M.D., Andrew Spencer, M.D., and Pieter Sonneveld, M.D., for the CASTOR Investigators NEngl J Med 2016;375:754-66. DOI: 10.1056/NEJMoa1606038

Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P. HLA polymorphism and risk of multiple myeloma. Leukemia. 2016 Jul 27. Leukemia volume 30, pages 2260–2264 doi: 10.1038/leu.2016.199.

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I,Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators.. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. . DOI: 10.1056/NEJMoa1606038

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A,Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J,Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016 Oct 14. pii: S2352-3026(16)30147-8. doi:10.1016/S2352-3026(16)30147-8. [Epub ahead of print] PubMed PMID: 27751707.

Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ,Nguyen TS, Cronier DM, Palumbo A. Phase 2 study of tabalumab, a human anti-B-cellactivating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2016 Dec 22. 176, 783–795 doi:10.1111/bjh.14483. [Epub ahead of print] PubMed PMID: 28005265.

Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016 Feb 11;127(6):713-21. doi: 10.1182/blood-2015-09-665018. Epub 2015 Dec 2. PMID:26631116

2017

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.

Sezer O, Beksac M, Hajek R, Sucak G ve ark. "Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: A randomized phase 2 study.", Br J Haem, 176(5) 783-795. March 2017 doi: 10.1111/bjh.14637. Epub

Dimopoulus MA, Lonial S, White D, Moreau P, Palumbo A, San- Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P, “Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.” Br J Haem, 178(6):896-905, September 2017 doi: 10.1111/bjh.14787. Epub 2017 Jul 5.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X,Beksac M , Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansson%20M%5BAuthor%5D&cauthor=true&cauthor_uid=28620163" > Hansson M , Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ , Moreau P, Kim K , Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM, “Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.”Leukemia, 31(11):2443-2448, Novenber 2017 DOI: 10.1038/leu.2017.138

 

2018

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Multiple Myeloma Treatment in Real-world Clinical Practice Results of a Prospective, Multinational, Noninterventional Study

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. “ Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.” Leukemia. 2018 Jul;32(7):1542-1560 doi: 10.1038/s41375-018-0040-1

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A “Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma”. Leuk Lymphoma. 2018 May 9:1-9. doi: 10.1080/10428194.2018.1459609

Weisel K, Sonneveld P, Spencer A, Beksac M, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A, “A Comparison of the Efficacy of Immunomodulatory-free Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis” Clinical Lymphoma Myeloma and Leukemia,Volume 18, Issue 3, March 2018, Pages 163-173.e6 doi: 10.1016/j.clml.2017.12.011

Insights on Multiple Myeloma Treatment Strategies

2019

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial